What is the recommended dose of Targocid (Teicoplanin) for a patient with Enterococcus faecium bacteremia and presumed normal renal function?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: January 30, 2026View editorial policy

Personalize

Help us tailor your experience

Which best describes you? Your choice helps us use language that's most understandable for you.

Teicoplanin Dosing for Enterococcus faecium Bacteremia

For Enterococcus faecium bloodstream infections in patients with normal renal function, administer teicoplanin with three loading doses of 6 mg/kg (or 400 mg) every 12 hours, followed by 6 mg/kg (or 400 mg) every 24 hours, with therapeutic drug monitoring targeting trough concentrations of 20-30 mg/L. 1, 2

Loading Dose Strategy

The critical first step is aggressive loading to achieve rapid therapeutic levels:

  • Administer 6 mg/kg (minimum 400 mg) every 12 hours for three doses 2
  • This loading phase is essential because teicoplanin is highly protein-bound (≥98%) and penetrates slowly into infected tissues 3
  • Without adequate loading, therapeutic levels may not be achieved for days, risking treatment failure 3

Maintenance Dosing

After loading, continue with:

  • 6 mg/kg (or 400 mg) once daily for patients with creatinine clearance 80-120 mL/min 4, 2
  • Reduce to 400 mg every 24 hours if creatinine clearance is <75 mL/min 4
  • Treatment duration should be 4-6 weeks for endocarditis and 7-14 days for uncomplicated bacteremia with effective source control 1, 5

Therapeutic Drug Monitoring Requirements

Target trough concentrations (Cmin) of 20-30 mg/L based on international guidelines for serious enterococcal infections: 1

  • Obtain first trough level before the 4th or 5th maintenance dose 1
  • Recheck levels weekly or after dose adjustments 1
  • In a recent study, only 62.7% of patients achieved target levels initially, but TDM-guided adjustments increased this to 85.1% 1
  • Microbiological eradication occurred in 95% of cases when target levels were achieved with effective source control 1

Critical Source Control Requirement

Failure to achieve source control was the only variable associated with microbiological failure (75% failure rate without source control vs. 12.7% with source control): 1

  • Remove infected catheters immediately for catheter-related bacteremia 1
  • Drain abscesses or biliary tract obstructions 1
  • Consider valve replacement for prosthetic valve endocarditis 4

Important Clinical Caveats

Teicoplanin should NOT be used as monotherapy for serious E. faecium infections without considering combination therapy: 3

  • Major guidelines recommend beta-lactam plus aminoglycoside combinations as first-line for enterococcal endocarditis 3
  • However, teicoplanin monotherapy achieved 95% microbiological eradication in recent TDM-guided studies for bacteremia 1
  • For endocarditis specifically, consider adding gentamicin for synergy if the isolate is aminoglycoside-susceptible 3

Advantages Over Vancomycin

Teicoplanin offers several practical benefits:

  • Once-daily dosing after loading (vs. twice-daily vancomycin) 2
  • Lower nephrotoxicity risk 2, 6
  • Can be administered intramuscularly for outpatient therapy 2, 6
  • Comparable efficacy to vancomycin (no significant mortality difference: 18.2% vs 26.6%, p=0.358) 5

Monitoring Parameters

  • Renal function weekly (creatinine clearance) 4
  • Teicoplanin trough levels before 4th-5th dose, then weekly 1
  • Follow-up blood cultures at 48-72 hours and after completing therapy 1
  • Liver enzymes and complete blood count (mild elevations and leucopenia reported in 7.7% of patients) 6

References

Research

Teicoplanin in the treatment of serious infection.

Journal of chemotherapy (Florence, Italy), 2000

Guideline

Guideline Directed Topic Overview

Dr.Oracle Medical Advisory Board & Editors, 2025

Research

Efficacy of teicoplanin in bloodstream infections caused by Enterococcus faecium: posthoc analysis of a nationwide surveillance.

International journal of infectious diseases : IJID : official publication of the International Society for Infectious Diseases, 2022

Research

Clinical efficacy and safety of teicoplanin.

The Journal of antimicrobial chemotherapy, 1988

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.